Non-alcoholic fatty liver disease in adults: Current concepts in etiology, outcomes and management.

Non-alcoholic fatty liver disease in adults: Current concepts in etiology, outcomes and management. Endocr Rev. 2019 Oct 20;: Authors: Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW Abstract Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disease, extending from simple steatosis, through to inflammation and fibrosis with a significant risk for the development of cirrhosis. It is highly prevalent and is associated with significant adverse outcomes both through liver-specific morbidity and mortality, but perhaps more importantly, through adverse cardiovascular and metabolic outcomes. It is tightly associated with type 2 diabetes and obesity and both of these conditions drive progressive disease towards the more advanced stages. The mechanisms that govern hepatic lipid accumulation and the predisposition to inflammation and fibrosis are still not fully understood, but reflect a complex interplay between metabolic target tissues including adipose and skeletal muscle, and immune and inflammatory cells. PMID: 31629366 [PubMed - as supplied by publisher]
Source: Endocrine Reviews - Category: Endocrinology Tags: Endocr Rev Source Type: research

Related Links:

This article reviews the most updated information about NAFLD-related HCC and provides some insight into strategies that must be considered to reduce its potential disease burden.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
(NAFLD) is a global health problem, with an estimated prevalence of 30% among adults in industrialized countries, and associated with obesity and type 2 diabetes mellitus. NAFLD is defined histologically and represents a spectrum from simple steatosis to steatohepatitis, fibrosis and cirrhosis. Hepatic triglyceride droplet accumulation is considered the first feature in the natural history; in some patients, this is associated with inflammation and fibrosis, through the interaction of environmental and host factors.
Source: Medicine - Category: Internal Medicine Authors: Tags: Common european liver disorders Source Type: research
CONCLUSION: Despite some limitations of our study, such as the small number of patients, and the use of two different methods of evaluation (biopsy and elastography), the data obtained allow us to conclude that of the 39 evaluated cases, 33% (13) presented progression of fibrosis and the total group of 50 patients, 42% had cirrhosis or died due to liver disease. The presence of NASH on hepatic biopsy did not prove to be, in our study, a predictive of the evolution of hepatic fibrosis in the patients.RESUMO CONTEXTO: A doen ça hepática gordurosa não alcoólica vem sendo diagnosticada com frequ&eci...
Source: Arquivos de Gastroenterologia - Category: Gastroenterology Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is a growing challenge to global public health. It is defined as the increased accumulation of hepatic triglyceride (>5%) in the absence of excessive alcohol consumption or other causes of liver disease. The NAFLD spectrum encompasses steatosis (non-alcoholic fatty liver, NAFL) and non-alcoholic steatohepatitis (NASH), an inflammatory form of the condition marked by the presence of hepatocyte damage and progressive fibrosis that may lead to cirrhosis.[1,2] Although NAFLD may occur in patients with normal weight, it is closely associated with the presence of the metabolic syndrom...
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Abstract Non-Alcoholic Fatty Liver Disease (NAFLD), the most common liver disease, is characterized by accumulation of fat (>5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. Its prevalence is increasing because of obesity, metabolic syndrome or Type 2 Diabetes Mellitus (T2DM). NAFLD can cause liver inflammation and progress to Non-Alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis or Hepatocellular Cancer (HCC). Nevertheless, Cardiovascular Disease (CVD) is the most common cause of morbidity and mortality in NAFLD/NASH patients. Current guidelines suggest the use of p...
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research
The prevalence of non-alcoholic fatty liver disease (NAFLD) has been increasing rapidly and at the forefront of worldwide concern. Characterized by excessive fat accumulation in the liver, NAFLD regularly coexists with metabolic disorders, including type 2 diabetes, obesity, and cardiovascular disease. It has been well established that the presence of NAFLD increases the incidence of type 2 diabetes, while diabetes aggravates NAFLD to more severe forms of steatohepatitis, cirrhosis, and hepatocellular carcinoma. However, recent progress on the genotype/phenotype relationships in NAFLD patients indicates the development of ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
With the growing prevalence of childhood obesity, pediatric non-alcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver disease in children and adolescents in Western countries.1 –3 NAFLD is a spectrum of progressive liver disease that encompasses simple steatosis, non-alcoholic steatohepatitis (NASH), advanced fibrosis and, ultimately, cirrhosis.3,4 Compelling evidence indicates that NAFLD also has serious health consequences outside of the liver and is strongly associate d with an increased risk of cardiovascular disease and abnormal glucose tolerance (prediabetes and type 2 diabetes).
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
With the growing prevalence of childhood obesity, pediatric non-alcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver disease in children and adolescents in Western countries [1 –3]. NAFLD is a spectrum of progressive liver disease that encompasses simple steatosis, non-alcoholic steatohepatitis (NASH), advanced fibrosis and, ultimately, cirrhosis [3,4]. Compelling evidence indicates that NAFLD also has serious health consequences outside of the liver and is strongly asso ciated with an increased risk of cardiovascular disease and abnormal glucose tolerance (prediabetes and type 2 diabetes) [5–7].
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
[Microbiome &NASH - partners in crime driving progression of fatty liver disease]. Z Gastroenterol. 2019 Jul;57(7):871-882 Authors: Wree A, Geisler LJ, Tacke F Abstract Along with the increasing prevalence of obesity, metabolic syndrome and type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) is rapidly increasing and poses a major challenge for gastroenterologists. Many studies have demonstrated that the microbiome is closely associated with the progression of nutrition-related diseases, especially of fatty liver disease. Changes in the quantity and quality of the intestinal flora, commonly...
Source: Zeitschrift fur Gastroenterologie - Category: Gastroenterology Authors: Tags: Z Gastroenterol Source Type: research
Abstract Non-alcoholic fatty liver disease (NAFLD) is histologically classified as either non-alcoholic fatty liver or non-alcoholic steatohepatitis (NASH). NASH is the progressive subtype of NAFLD. Individuals with NASH are at significant risk of developing hepatic fibrosis, cirrhosis, hepatocellular carcinoma, and liver-related and all-cause mortality. NAFLD is closely associated with obesity, type 2 diabetes mellitus (T2DM), metabolic syndrome, and cardiovascular events. Its prevalence is estimated to be above 30% in Turkey; and recent studies confirm this estimate. According to these studies, the prevalence of...
Source: The Turkish Journal of Gastroenterology - Category: Gastroenterology Authors: Tags: Turk J Gastroenterol Source Type: research
More News: Alcoholism | Cardiology | Cardiovascular | Cirrhosis | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Heart | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Urology & Nephrology